ASTRAZENECA PLC — All Filings
1,000 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
11-K
144
20-F
20-F/A
25
25-NSE
3
3/A
4
424B2
424B3
424B5
425
6-K
6-K/A
8-A12B
8-A12B/A
CERT
CERTNYS
CORRESP
CT ORDER
DFAN14A
EFFECT
F-3
F-3ASR
F-4
F-4/A
F-6
F-6 POS
F-6EF
FWP
IRANNOTICE
NO ACT
S-1
S-8
S-8 POS
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SC TO-C
SC TO-T
SC TO-T/A
SCHEDULE 13D/A
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 6-K | TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS | 0001654954-26-002860 | Mar 27, 2026 | — |
| 6-K | NOTIFICATION OF ADMISSION OF SHARES | 0001654954-26-002523 | Mar 20, 2026 | — |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-032249 | Mar 19, 2026 | Mar 18, 2026 |
| 6-K | IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER | 0001654954-26-002272 | Mar 16, 2026 | — |
| 6-K | NOTICE OF AGM | 0001654954-26-002077 | Mar 10, 2026 | — |
| 6-K | FORM 6-K | 0001104659-26-025559 | Mar 10, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001966 | Mar 6, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001963 | Mar 6, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001961 | Mar 6, 2026 | — |
| CERT | NYSE CERTIFICATION | 0000876661-26-000201 | Mar 4, 2026 | — |
| 8-A12B | FORM 8-A12B | 0001104659-26-022824 | Mar 3, 2026 | — |
| 6-K | FORM 6-K | 0001104659-26-022240 | Mar 2, 2026 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-26-001728 | Mar 2, 2026 | — |
| 424B2 | 424B2 | 0001104659-26-021545 | Feb 27, 2026 | — |
| 6-K | ASTRAZENECA PRICES A $2BN BOND OFFERING | 0001654954-26-001589 | Feb 26, 2026 | — |
| FWP | FWP | 0001104659-26-019812 | Feb 26, 2026 | — |
| 6-K | FILING OF FORM 20-F WITH SEC | 0001654954-26-001536 | Feb 25, 2026 | — |
| 424B2 | 424B2 | 0001104659-26-019420 | Feb 25, 2026 | — |
| IRANNOTICE | IRANNOTICE | 0001104659-26-019141 | Feb 24, 2026 | — |
| 20-F | 20-F | 0001104659-26-019130 | Feb 24, 2026 | Dec 31, 2025 |
| 6-K | FORM 6-K | 0001104659-26-019110 | Feb 24, 2026 | — |
| 6-K | ANNUAL FINANCIAL REPORT | 0001654954-26-001483 | Feb 24, 2026 | — |
| 6-K | DIRECTORATE CHANGE | 0001654954-26-001481 | Feb 24, 2026 | — |
| 6-K | FIXED-DURATION CALQUENCE COMBO APPROVED IN US | 0001654954-26-001409 | Feb 20, 2026 | — |
| 6-K | FINAL RESULTS | 0001654954-26-001073 | Feb 10, 2026 | — |
| SCHEDULE 13G/A | — | 0001104659-26-011303 | Feb 6, 2026 | — |
| SCHEDULE 13D/A | — | 0001104659-26-011298 | Feb 6, 2026 | — |
| 6-K | UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION | 0001654954-26-000857 | Feb 3, 2026 | — |
| S-8 | FORM S-8 | 0001104659-26-009284 | Feb 2, 2026 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-26-000824 | Feb 2, 2026 | — |
| 6-K | IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER | 0001654954-26-000795 | Feb 2, 2026 | — |
| 6-K | ASTRAZENECA BEGINS TRADING ON NYSE | 0001654954-26-000792 | Feb 2, 2026 | — |
| 25 | FORM 25 | 0001104659-26-008613 | Jan 30, 2026 | — |
| 6-K | ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC | 0001654954-26-000730 | Jan 30, 2026 | — |
| 6-K | ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030 | 0001654954-26-000688 | Jan 29, 2026 | — |
| CERT | NYSE CERTIFICATION | 0000876661-26-000055 | Jan 22, 2026 | — |
| 8-A12B | 8-A12B | 0001104659-26-005799 | Jan 22, 2026 | — |
| CERT | NYSE CERTIFICATION | 0000876661-26-000054 | Jan 22, 2026 | — |
| 8-A12B | 8-A12B | 0001104659-26-005772 | Jan 22, 2026 | — |
| 6-K | ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE | 0001654954-26-000464 | Jan 20, 2026 | — |
| 6-K | AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON | 0001654954-26-000153 | Jan 8, 2026 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-26-000027 | Jan 2, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-014171 | Dec 22, 2025 | — |
| 6-K | ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC | 0001654954-25-014166 | Dec 22, 2025 | — |
| 6-K | UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB | 0001654954-25-014164 | Dec 22, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-014136 | Dec 19, 2025 | — |
| 6-K | SUBCUTANEOUS SAPHNELO APPROVED IN EU | 0001654954-25-013974 | Dec 16, 2025 | — |
| 6-K | ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC | 0001654954-25-013970 | Dec 16, 2025 | — |
| 6-K | HOLDING(S) IN COMPANY | 0001654954-25-013678 | Dec 4, 2025 | — |
| 6-K | BLOCK LISTING INTERIM REVIEW | 0001654954-25-013569 | Dec 1, 2025 | — |